Skip to main content
Fig. 3 | Cancer Imaging

Fig. 3

From: 18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Fig. 3

Axial PET/CT data sets of representative tumors from therapy and control group. Top row: 18F–FDG-PET/CT data sets. Bottom row: CT data sets. a therapy group, baseline. b therapy group, follow-up. c control group, baseline. d control group, follow-up. Note the significantly suppressed tumor glucose uptake following the 1-week BRAF and CDK 4/6 inhibitor combination therapy (b vs. a). Note the significant increase in tumor glucose uptake and tumor volume in the control group (d vs. c)

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us